Glucagon Receptor

The glucagon receptor (GCGR) is a class B G protein-coupled receptor expressed predominantly in the liver, with additional expression in the kidneys, heart, adipose tissue, and central nervous system. It mediates the effects of glucagon, the counter-regulatory hormone to insulin. For decades, glucagon was viewed simply as the hormone that raises blood sugar — the opposite of insulin, and therefore something to suppress in metabolic disease. That understanding has been replaced by a more nuanced view: controlled glucagon receptor activation, when combined with GLP-1 and/or GIP receptor agonism, can produce metabolic benefits that exceed those of GLP-1 agonism alone.

Glucagon: the hormone

Glucagon is a 29-amino acid peptide hormone secreted by alpha cells of the pancreatic islets in response to low blood glucose, amino acid ingestion, and sympathetic nervous system activation. It is the primary counter-regulatory hormone to insulin, and its principal role is preventing hypoglycemia during fasting.

Glucagon secretion is suppressed by high blood glucose, insulin, somatostatin, and GLP-1. In type 2 diabetes, this suppression is impaired — alpha cells continue secreting glucagon even when blood glucose is elevated, contributing to fasting and postprandial hyperglycemia.

Receptor structure and signaling

GCGR belongs to the secretin receptor family (class B GPCRs), the same family that includes the GLP-1 receptor and GIP receptor. This structural homology is what makes it possible to engineer single peptide molecules that activate two or three of these receptors simultaneously.

Upon glucagon binding, GCGR activates the Gs alpha subunit, stimulating adenylyl cyclase to produce cyclic AMP (cAMP). cAMP activates protein kinase A (PKA), which phosphorylates downstream targets including CREB (cAMP response element-binding protein). This cAMP/PKA/CREB axis drives the transcriptional and metabolic changes that characterize glucagon action.

Metabolic effects of glucagon receptor activation

Hepatic glucose production

This is glucagon's classical role. GCGR activation in hepatocytes stimulates:

• Glycogenolysis: Rapid breakdown of hepatic glycogen stores to release glucose into the circulation. This is the immediate response (minutes) and is the primary defense against acute hypoglycemia
• Gluconeogenesis: Synthesis of new glucose from non-carbohydrate precursors (lactate, alanine, glycerol). This is the sustained response (hours) that maintains blood glucose during prolonged fasting

Both processes are mediated through PKA-dependent phosphorylation of glycogen phosphorylase (activating glycogenolysis) and transcriptional upregulation of gluconeogenic enzymes (PEPCK, G6Pase) via CREB and FOXO1.

Hepatic lipid metabolism

This effect is increasingly recognized as therapeutically important:

• Increased fatty acid oxidation: Glucagon activates hepatic beta-oxidation, burning fat stores in the liver
• Decreased lipogenesis: Glucagon suppresses de novo fatty acid synthesis by inhibiting acetyl-CoA carboxylase (ACC) and sterol regulatory element-binding protein 1c (SREBP-1c)
• Reduced hepatic triglyceride content: The net effect is depletion of intrahepatic fat, which is directly relevant to non-alcoholic fatty liver disease (NAFLD/MASLD)

Energy expenditure

Glucagon increases resting energy expenditure through multiple mechanisms:

• Hepatic thermogenesis: Increased substrate cycling (simultaneous gluconeogenesis and glycolysis) wastes energy as heat
• Brown adipose tissue activation: GCGR signaling in brown fat (where expressed) increases uncoupling protein 1 (UCP1) activity
• Amino acid catabolism: Glucagon promotes hepatic amino acid oxidation, which is energetically costly

This increase in energy expenditure — estimated at 50 to 200 kcal/day in human studies — is modest but meaningful when sustained over months.

Appetite effects

Glucagon has central anorexigenic effects independent of its metabolic actions. GCGR activation in the hypothalamus and brainstem reduces food intake, though the mechanism is less well characterized than the appetite suppression produced by GLP-1.

The problem with glucagon alone

If glucagon increases energy expenditure, burns liver fat, and reduces appetite, why not use it as a standalone therapy? Because of the glucose problem.

Unopposed glucagon receptor activation raises blood glucose. In individuals with normal beta cell function, this triggers compensatory insulin secretion that restores normoglycemia. But in patients with impaired beta cell function (type 2 diabetes, prediabetes), glucagon-driven hepatic glucose output is not adequately countered by insulin, resulting in hyperglycemia.

This is why glucagon receptor activation is only therapeutically viable when combined with GLP-1 receptor agonism, which:

• Stimulates glucose-dependent insulin secretion (countering glucagon's hyperglycemic effect)
• Suppresses endogenous glucagon secretion from alpha cells
• Slows gastric emptying (reducing postprandial glucose excursions)
• Provides additional appetite suppression

Dual and triple agonist peptides

The recognition that controlled GCGR activation adds metabolic benefits beyond GLP-1 alone has driven the development of multi-receptor agonist peptides.

GLP-1/glucagon dual agonists

These peptides activate both GLP-1R and GCGR. The GLP-1 component handles glycemic control and appetite suppression, while the glucagon component adds energy expenditure, hepatic fat reduction, and additional weight loss.

Survodutide (BI 456906) is the most advanced GLP-1/glucagon dual agonist. In Phase 2 trials, survodutide produced up to 18.7% body weight reduction at 46 weeks and significant reductions in liver fat content, with Phase 3 trials ongoing in both obesity and MASLD/NASH.

The glucagon component is what differentiates survodutide from pure GLP-1 agonists: the liver fat reduction and energy expenditure increase are effects that GLP-1 agonism alone cannot fully replicate.

GLP-1/GIP/glucagon triple agonists

Retatrutide (LY3437943) activates all three incretin-related receptors: GLP-1R, GIPR, and GCGR. In Phase 2 trials, retatrutide produced up to 24.2% body weight reduction at 48 weeks — the highest weight loss reported for any anti-obesity medication to date in a Phase 2 setting.

The triple mechanism is theorized to work through complementary pathways:

• GLP-1R: Appetite suppression, glycemic control
• GIPR: Enhanced insulin sensitivity, possible adipose tissue remodeling
• GCGR: Energy expenditure increase, hepatic fat clearance

Balancing the ratio

The therapeutic challenge in multi-agonist design is calibrating the relative potency at each receptor. Too much glucagon agonism relative to GLP-1 produces hyperglycemia. Too little glucagon agonism fails to add meaningful metabolic benefit beyond GLP-1 alone. The ratio of GLP-1 to glucagon activity in survodutide and retatrutide was determined through extensive dose-ranging studies to find the metabolic sweet spot.

GCGR and hepatic amino acid metabolism

A recently appreciated function of glucagon is its role in hepatic amino acid clearance. Glucagon receptor activation upregulates urea cycle enzymes and amino acid transporters, increasing the liver's capacity to catabolize amino acids. Loss of GCGR signaling (genetic knockout or pharmacological blockade) causes hyperaminoacidemia, which in turn drives alpha cell hyperplasia and paradoxical hyperglucagonemia.

This glucagon-amino acid feedback loop has clinical implications: elevated plasma amino acid levels may serve as a biomarker of hepatic glucagon resistance, and some researchers propose that glucagon's primary evolutionary role may be amino acid homeostasis rather than glucose regulation.

GCGR antagonism: the other approach

While multi-agonist peptides incorporate glucagon activation, a separate pharmacological strategy targets glucagon receptor antagonism for diabetes. The rationale is straightforward: blocking glucagon action reduces hepatic glucose output, lowering blood sugar.

GCGR antagonists have shown glucose-lowering efficacy in clinical trials, but with concerning side effects: increased hepatic fat (because the lipid-burning effects of glucagon are also blocked), LDL cholesterol elevation, alpha cell hyperplasia, and increases in blood pressure. These side effects have largely stalled GCGR antagonist development and reinforced the view that modulating glucagon action — not abolishing it — is the better therapeutic strategy.

Bottom line

The glucagon receptor is the third pillar of multi-agonist peptide pharmacology alongside GLP-1R and GIPR. Glucagon receptor activation increases energy expenditure, accelerates hepatic fat clearance, promotes amino acid catabolism, and provides modest appetite suppression — effects that complement GLP-1-mediated glycemic control and appetite reduction. The key insight is that glucagon agonism is beneficial only when paired with sufficient GLP-1 agonism to prevent hyperglycemia. This principle underlies the design of survodutide (GLP-1/GCGR dual agonist) and retatrutide (GLP-1/GIP/GCGR triple agonist), which represent the current frontier of peptide-based metabolic therapy.